Breast Cancer

This phase 1b clinical trial evaluates the dose response and safety of alpelisib plus fulvestrant treatment in women with advanced breast cancer.

This Viewpoint analyzes data on the thrombotic risk associated with cyclin-dependent kinase inhibitors and notes the need for additional research on the thrombotic risk of these drugs, the influence of combined drug therapy on thrombotic risk, and patient selection.

This study examines HER2 ISH-equivocal breast cancers to asses 2013/2014 American Society of Clinical Oncology and College of American Pathologists guidelines in determining HER2-positive or HER2-negative breast cancers and false-positive results.

This secondary analysis of the Women’s Health Initiative randomized clinical trial and observational study cohort investigates the association between body fat and breast cancer risk in postmenopausal women with normal body mass index.

This secondary analysis of a randomized clinical trial investigates the association of circulating tumor cells with recurrence of breast cancer 5 or more years after diagnosis among patients with hormone receptor–positive breast cancer.

This cohort study of female participants with stage 0 to IIA breast cancer treated with breast-conserving surgery and whole-breast irradiation assesses whether radiation-induced toxicities of normal breast tissue 3 years after radiotherapy are associated with the transforming growth factor β gene variant C−509T.

This biomarker study estimates the diversity of T-cell populations in the tumor microenvironment by assessing messenger RNA expression of the T-cell receptor β chain variable gene from RNA sequencing data of pretreatment biopsies of women with HER2-positive breast cancer in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial.

This pooled analysis of individual patient data investigates the association of body mass index with subsequent breast cancer risk, in particular by age, attained age, risk factors for breast cancer, and tumor characteristics, in premenopausal women.

This Viewpoint discusses the use of hypofractionation for regional nodal irradiation as part of radiotherapy for breast cancer and the importance of waiting for results of long-term prospective studies.

This cost-effectiveness study uses a life-table model of a hypothetical cohort of 364 500 women to evaluate the cost-effectiveness and benefit to harm ratio of risk-stratified screening for breast cancer.

This Viewpoint assesses the use of low-dose bisphosphonates to reduce the risks of bone metastases and mortality in postmenopausal patients with early breast cancer.

This survey study examines the propensity of surgeons to use axillary lymph node biopsy alone for axillary management in women with early-stage breast cancer undergoing breast-conserving surgery.